Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pilot Study of Diflunisal in HIV-infected Adults
NCT01676363 · University of British Columbia · PHASE4 · terminated · last registry update 2017-10-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient enrollment.” | – | Registry record, University of British Columbia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGS2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-04-26Also stopped (terminated): Vicus Therapeutics, VT-122 + Placebo (NCT01857817)
- 2018-02-15Phase 3 first posted: Taisho Pharmaceutical Co., Ltd., Esflurbiprofen + Diclofenac diethylamine (NCT03434197)
- 2017-04-25Phase 3 first posted: Apsen Farmaceutica S.A., Fixed Dose Combination + Etodolac (NCT03127592)
- 2017-03-17Results posted on the registry: Boston University, diflunisal (NCT00294671)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision